EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

OTC Pharmaceuticals in United Arab Emirates

  • ID: 2113055
  • Report
  • September 2014
  • Region: United Arab Emirates
  • 39 pages
  • MarketLine
1 of 4
Introduction

OTC Pharmaceuticals in United Arab Emirates industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Arab Emirates otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2013 annual average exchange rates.

- The Emirati OTC pharmaceuticals market had total revenues of $255.5m in 2013, representing a compound annual growth rate (CAGR) of 7.6% between 2009 and 2013.

- The analgesics segment was the market's most lucrative in 2013, with total revenues of $61.5m, equivalent to 24.1% of the market's overall value.

- The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.2% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $313.8m by the end of 2018.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the otc pharmaceuticals market in United Arab Emirates

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in United Arab Emirates

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the United Arab Emirates otc pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the United Arab Emirates economy

Key Questions Answered

What was the size of the United Arab Emirates otc pharmaceuticals market by value in 2013?

What will be the size of the United Arab Emirates otc pharmaceuticals market in 2018?

What factors are affecting the strength of competition in the United Arab Emirates otc pharmaceuticals market?

How has the market performed over the last five years?
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Executive Summary

Market value

Market value forecast

Category segmentation

Geography segmentation

Market share

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market Segmentation

Category segmentation

Geography segmentation

Market share

Market distribution

Market Outlook

Market value forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Bayer AG

GlaxoSmithKline Plc

Johnson & Johnson

Novartis AG

Macroeconomic Indicators

Country Data

Appendix

Methodology

Industry associations

Related research

LIST OF TABLES

Table 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2009–13

Table 2: United Arab Emirates OTC pharmaceuticals market category segmentation: $ million, 2013

Table 3: United Arab Emirates OTC pharmaceuticals market geography segmentation: $ million, 2013

Table 4: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2013

Table 5: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2013

Table 6: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2013–18

Table 7: Bayer AG: key facts

Table 8: Bayer AG: key financials ($)

Table 9: Bayer AG: key financials (€)

Table 10: Bayer AG: key financial ratios

Table 11: GlaxoSmithKline Plc: key facts

Table 12: GlaxoSmithKline Plc: key financials ($)

Table 13: GlaxoSmithKline Plc: key financials (£)

Table 14: GlaxoSmithKline Plc: key financial ratios

Table 15: Johnson & Johnson: key facts

Table 16: Johnson & Johnson: key financials ($)

Table 17: Johnson & Johnson: key financial ratios

Table 18: Novartis AG: key facts

Table 19: Novartis AG: key financials ($)

Table 20: Novartis AG: key financial ratios

Table 21: United Arab Emirates size of population (million), 2009–13

Table 22: United Arab Emirates gdp (constant 2005 prices, $ billion), 2009–13

Table 23: United Arab Emirates gdp (current prices, $ billion), 2009–13

Table 24: United Arab Emirates inflation, 2009–13

Table 25: United Arab Emirates consumer price index (absolute), 2009–13

Table 26: United Arab Emirates exchange rate, 2009–13

LIST OF FIGURES

Figure 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2009–13

Figure 2: United Arab Emirates OTC pharmaceuticals market category segmentation: % share, by value, 2013

Figure 3: United Arab Emirates OTC pharmaceuticals market geography segmentation: % share, by value, 2013

Figure 4: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2013

Figure 5: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2013

Figure 6: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2013–18

Figure 7: Forces driving competition in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in United Arab Emirates, 2013

Figure 13: Bayer AG: revenues & profitability

Figure 14: Bayer AG: assets & liabilities

Figure 15: GlaxoSmithKline Plc: revenues & profitability

Figure 16: GlaxoSmithKline Plc: assets & liabilities

Figure 17: Johnson & Johnson: revenues & profitability

Figure 18: Johnson & Johnson: assets & liabilities

Figure 19: Novartis AG: revenues & profitability

Figure 20: Novartis AG: assets & liabilities
Note: Product cover images may vary from those shown
3 of 4
GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG and WellSpring Pharmaceuticals
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll